


# DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models

Zhen Chen, ... , Suresh S. Ramalingam, Shi-Yong Sun

*J Clin Invest.* 2024. <https://doi.org/10.1172/JCI172716>.

Research In-Press Preview Oncology Therapeutics

## Graphical abstract



Find the latest version:

<https://jci.me/172716/pdf>



**DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy  
in EGFR-mutant non-small cell lung cancer models**

Zhen Chen<sup>1</sup>, Karin A. Vallega<sup>1</sup>, Dongsheng Wang<sup>1</sup>, Zihan Quan<sup>2</sup>, Songqing Fan<sup>2</sup>, Qiming Wang<sup>3</sup>,  
Ticiana Leal<sup>1</sup>, Suresh S. Ramalingam<sup>1</sup>, Shi-Yong Sun<sup>1</sup>

*<sup>1</sup>Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA; <sup>2</sup>Department of Pathology, The Second Xiangya Hospital, South Central University, Changsha, Hunan, P. R. China; and <sup>3</sup>Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China;*

**Running title:** EGFR-TKI inhibition of Topo II in NSCLC

**Disclosure of potential conflicts of interest:** TL is on consulting/advisory board for Eisai, Merck, Roche/Genentech, Jazz Pharmaceuticals, Catalyst, OncoC4, Amgen, AstraZeneca, Pfizer, Regeneron, Janssen, Novartis, Novocure and Sanofi. SSR is on consulting/advisory boards for AstraZeneca, BMS, Merck, Roche, Tesaro and Amgen. Other authors disclose that they have no potential conflicts of interest.

**Request for reprints:** Shi-Yong Sun, Ph.D., Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, 1365-C Clifton Road, C3088, Atlanta, GA 30322. Phone: (404) 778-2170; Fax: (404) 778-5520; Email: ssun@emory.edu.

## Abstract

Development of effective strategies to manage the inevitable acquired resistance to osimertinib, an approved 3<sup>rd</sup> generation EGFR inhibitor for the treatment of EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC), is urgently needed. This study reported that the DNA topoisomerase II (Topo II) inhibitors, doxorubicin and etoposide (VP-16) synergistically decreased cell survival with enhanced induction of DNA damage and apoptosis in osimertinib-resistant cells, suppressed the growth of osimertinib-resistant tumors, and delayed the emergence of osimertinib acquired resistance. Mechanistically, osimertinib decreased Topo II $\alpha$  levels in EGFRm NSCLC cells by facilitating FBXW7-mediated proteasomal degradation, resulting in induction of DNA damage; these effects were lost in osimertinib-resistant cell lines possessing elevated levels of Topo II $\alpha$ . Topo II $\alpha$  elevation was also detected in the majority of EGFRm NSCLC tissues relapsed from EGFR-TKI treatment. Enforced expression of an ectopic *TOP2A* gene in sensitive EGFRm NSCLC cells conferred resistance to osimertinib, whereas knockdown of *TOP2A* in osimertinib-resistant cell lines restored their response to undergo osimertinib-induced DNA damage and apoptosis. Together, these results reveal an essential role of Topo II $\alpha$  inhibition in mediating the therapeutic efficacy of osimertinib against EGFRm NSCLC, providing scientific rationale for targeting Topo II to manage acquired resistance to osimertinib.

**Key words:** EGFR-TKIs, osimertinib, topoisomerase II, DNA damage, apoptosis, lung cancer

**Abbreviations:** EGFR, Epidermal growth factor receptor; EGFRm, EGFR mutant; NSCLC, non-small cell lung cancer; EGFR-TKIs, EGFR-tyrosine kinase inhibitors; Topo II, DNA topoisomerase II (Topo II); DXR, doxorubicin; VP-16, etoposide; DSB, double-strand breaks; AR, AZD9292-resistant; CI, combination index; SRB, sulforhodmanine B; siRNA, small interfering RNA; shRNA, short-hairpin RNA; IF, immunofluorescence; IHC, immunohistochemistry; PDX, patient-derived xenograft.

## **Introduction**

Lung cancer has remained the leading cause of cancer death among both men and women, and accounts for around one-fourth of all cancer deaths worldwide despite great efforts to improve outcomes in the past decades. Advances in the development of various targeted therapies and immunotherapy have substantially improved the 5-year survival rate of lung cancer in the US, although it is still low at around 20% (1). The discovery of epidermal growth factor receptor (EGFR) activating mutations as a predictor of patient response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) represented a milestone and paradigm shift in the treatment of non-small cell lung cancer (NSCLC). As the first successful targeted therapy against lung cancer, EGFR-targeted therapy has contributed to improving the quality of life and survival of lung cancer patients.

However, the key challenge in clinical practice is the inevitable development of acquired resistance, limiting the long-term benefit of this targeted therapy. Advances in the field to battle against acquired resistance have led to the rapid development of new generation EGFR-TKIs from the initial first generation (e.g., erlotinib and gefitinib) to 2<sup>nd</sup> generation (e.g., afatinib) and the current 3<sup>rd</sup> generation (e.g., osimertinib or AZD9291) agents. Third generation EGFR-TKIs are described as mutation-selective EGFR-TKIs because of their selective and irreversible effects against EGFR activating and T790M resistant mutations. Among them, osimertinib is the first FDA-approved EGFR-TKI for patients with EGFR mutant (EGFR<sub>m</sub>) NSCLC whose disease has become resistant to 1<sup>st</sup> generation EGFR-TKIs through the T790M mutation as a second-line treatment and for EGFR<sub>m</sub> advanced NSCLC as a first line treatment. Osimertinib has demonstrated impressive activity in prolonging overall survival (OS) of patients for over 3 years (2). Despite this, acquired resistance inevitably occurs to osimertinib and other 3<sup>rd</sup> generation

EGFR-TKIs (3-5). Thus, the development of effective strategies to overcome acquired resistance to 3<sup>rd</sup> generation EGFR-TKIs is an urgent and critical area of unmet need in the clinic.

Conventional cytotoxic chemotherapy remains the mainstay of treatment for many cancer types including NSCLC. Platinum-based doublet chemotherapy has been the backbone of NSCLC treatment for decades and still represents a key therapeutic option even in the era of modern immunotherapy (6, 7). It is also an option for EGFRm NSCLC patients who have disease relapse from osimertinib and have no other treatment options. However, it is unclear whether there is a role for chemotherapy in managing acquired resistance to osimertinib and, if so, what the scientific rationale is for choosing the optimal chemotherapeutic agents, even though chemotherapy is used in the treatment of osimertinib-relapsed patients in real world clinical practice. In our effort toward understanding and overcoming acquired resistance to osimertinib, we found that the DNA topoisomerase II (Topo II) inhibitors, doxorubicin (DXR; adriamycin) and etoposide (VP-16), but not other chemotherapeutic agents such as cisplatin, carboplatin, and paclitaxel, synergized with osimertinib to decrease the survival of several osimertinib-resistant cell lines accompanied with enhanced induction of apoptosis, suggesting their unique potential in overcoming acquired resistance to osimertinib.

Topo II is a well-known cancer target. Both DXR and VP-16, although less frequently used in NSCLC, act by trapping Topo II on to DNA to increase the levels of Topo II–DNA covalent complexes, thereby preventing DNA replication and transcription, and causing DNA single- and double-strand breaks (DSBs; or DNA damage) which in turn result in apoptosis when not adequately repaired (6, 8). It has been shown that inhibition of EZH2, a methyltransferase, sensitizes EGFR mutant (EGFRm) lung tumors to Topo II inhibitors such as VP-16, suggesting that dual inhibition of EZH2 plus Topo II represents a treatment option for EGFRm tumors (9).

Hence, we focused on demonstrating the efficacy of Topo II inhibitor, particularly VP-16, in overcoming acquired osimertinib resistance when combined with osimertinib and on defining the underlying scientific rationale. As a result, we confirmed the effects of osimertinib in combination with a Topo II inhibitor on the growth of osimertinib-resistant xenograft tumor *in vivo* and on delaying the emergence of acquired resistance to osimertinib. Consistently, osimertinib as well as other EGFR-TKIs decreased the levels of Topo II $\alpha$  in EGFR<sub>m</sub> NSCLC cells accompanied with increased DNA damage; these effects were lost in osimertinib-resistant cell lines that possessed elevated basal levels of Topo II $\alpha$ . Importantly, knockdown of *TOP2A* in osimertinib-resistant EGFR<sub>m</sub> NSCLC cell lines sensitized their responses to osimertinib including induction of DNA damage and apoptosis, whereas enforced overexpression of *TOP2A* in sensitive EGFR<sub>m</sub> NSCLC cells conferred resistance to osimertinib. These findings together demonstrate a novel connection between Topo II modulation and therapeutic efficacy of EGFR-targeted therapy, thus providing a scientific rationale for targeting Topo II to delay and overcome acquired resistance to osimertinib as well as other EGFR-TKIs.

## Results

**Chemotherapeutic agents with Topo II-inhibitory activity combined with osimertinib exhibits potentiated effects on decreasing the survival and inducing Bim-dependent apoptosis of osimertinib-resistant cell lines.** To determine whether any chemotherapeutic agents, when combined with osimertinib, enhance the decreased survival of osimertinib-resistant cells, we screened the efficacies of 10 commonly used chemotherapeutic agents combined with osimertinib, respectively, against the growth of the two EGFR<sub>m</sub> NSCLC cell lines with acquired resistance to osimertinib, PC-9/AR and HCC827/AR. Among them, DXR and VP-16 stood out as the only two

agents that were significantly more effective than either agent alone, when combined with osimertinib, in decreasing the survival of these two cell lines (Figs. 1A and S1). The combination of osimertinib with either DXR or VP-16 was synergistic in decreasing the survival of both PC-9/AR and HCC827/AR cell lines given the combination indexes (CIs) were  $< 1$  (Figs. 1B and C). The colony formation assay, which allows us to repeat the treatments for a relatively long period of time, further demonstrated that the combination of osimertinib with either DXR or VP-16 was significantly more active than either single agent in inhibiting the formation and growth of PC-9/AR and HCC827/AR colonies (Figs. 1D and E). The combinations were also significantly more effective than either agent alone in the induction of apoptosis evidenced by enhanced cleavage of both PARP and caspase-3 (Fig. 1F) and annexin V-positive cells (Fig. 1G) in both PC-9/AR and HCC827/AR cells. In agreement, we also detected enhanced effects of osimertinib with DXR on decreasing the survival, inhibiting colony formation and growth, and inducing apoptosis of PC-9/GR/AR cells (Fig. S2).

Osimertinib is known to induce apoptosis via modulating Bim and Mcl-1 levels in EGFRm NSCLC cells (10). To demonstrate whether the combination of osimertinib with DXR or VP-16 results in enhanced apoptosis via altering the levels of Bim and Mcl-1, we then assessed the effects of the combinations on the levels of these proteins in PC-9/AR and HCC827/AR cells lines. Whereas osimertinib, DXR, or VP-16 alone did not increase Bim levels or decrease Mcl-1 levels, the combination of osimertinib with DXR or VP-16 effectively elevated Bim levels while decreasing Mcl-1 levels in these two cell lines (Fig. 1H). Accordingly, the combination of osimertinib with VP-16 led to greater induction of PARP cleavage and increase in annexin V-positive cells in PC-9/AR cells, but not in PC-9/AR-Bim KO cells (Figs. 1I and J). Similar results were generated in HCC827/AR-Bim KO cells (Fig. S3). These data together demonstrate that the



combination of osimertinib with DXR or VP-16 enhances Bim-dependent apoptosis in osimertinib-resistant cells and the inclusion of DXR or VP-16 restores the ability of osimertinib to induce Bim-dependent apoptosis in osimertinib-resistant cells.

**The combination of osimertinib with a Topo II inhibitor effectively inhibits the growth of osimertinib-resistant tumors *in vivo* and is well tolerated in mice.** We next examined the effects of the combinations of osimertinib with DXR and VP-16, respectively, on the growth of osimertinib-resistant xenografts in nude mice. As presented in Fig. 2, the combination of osimertinib with either VP-16 or DXR was significantly more effective than either agent alone in inhibiting the growth of PC-9/AR or HCC827/AR tumors based on changes in both tumor size and weight (Figs. 2A-C). Hence, it is clear that the combination of osimertinib and a Topo II inhibitor effectively inhibits the growth of osimertinib-resistant tumors *in vivo*. Mice receiving the combinations had body weight comparable to those treated with either single agent alone (Fig. S4), demonstrating that the combinations do not enhance toxicity in mice while potentiating therapeutic efficacy. We further detected the levels of Ki-67, a well-known cell proliferation marker, cleaved PARP (cPARP), a hallmark of apoptosis, and Bim and Mcl-1, two critical apoptosis-regulating proteins modulated by the combinations as demonstrated above, in tumor tissues receiving these treatments. As shown in Fig. 2D, the tissues from mice treated with both combinations displayed the fewest Ki-67-positive cells and the most cPARP-positive cells in comparison with other tissues receiving osimertinib, VP-16 or DXR treatment, further indicating that the combinations exert enhanced growth-inhibitory effects with augmented induction of apoptosis against osimertinib-resistant tumors. In agreement with increased cPARP, the highest levels of Bim and lowest levels of Mcl-1 were detected in tissues receiving the combination treatment in comparison with tissues

treated with each single agent (Fig. 2D), validating our finding of the critical roles of Bim and Mcl-1 modulation in mediating enhanced apoptosis by the combination *in vivo*.

Moreover, we compared the effects of osimertinib combined with VP-16, cisplatin (CDDP) and paclitaxel (PTX; taxol), respectively, on the growth of HCC827/AR tumors under the same condition. While the combination of osimertinib with VP-16 effectively inhibited the growth of HCC827/AR tumors more significantly than either single agent alone, as demonstrated above, the combination of osimertinib with either CDDP or PTX failed to show enhanced effect on suppressing the growth of HCC827 tumors (Fig. S5). This data is consistent with our *in vitro* finding as presented above.

Considering that the above *in vivo* experiments were conducted in nude mice that are immune-compromised, we then examined the potential toxicities of osimertinib combined with VP-6 and DXR, respectively, with the same treatments used above in immunocompetent mice. After 5-weeks treatments, the mouse body weights in the combination groups were comparable with those in the single agent treatment groups (Fig. S6A). The histological examination of tissues from the major organs including heart, liver, lung, kidney and spleen among the different groups did not show a difference (Fig. S6B). The detection of various serum proteins or enzymatic activities among the tested groups did not show a significant difference either (Fig. S6C). Hence, the combinations are well-tolerated in the immunocompetent mice as well.

**Osimertinib decreases Topo II $\alpha$  levels, resulting in induction of DNA damage and subsequent apoptosis in EGFR<sup>m</sup> NSCLC cell lines.** We were interested in the mechanisms underlying the activity of DXR and VP-16 in overcoming acquired resistance to osimertinib as demonstrated above. One common property of DXR and VP-16 is that they are both Topo II inhibitors, making them distinct from other chemotherapeutic agents tested. TCGA data analysis

revealed that *TOPA2* expression was significantly higher in lung adenocarcinoma tissues than in normal tissues (Fig. S7A) and was significantly associated with reduced OS (Fig. S7B). In EGFRm lung adenocarcinoma, high *TOP2A* expression was also significantly associated with reduced OS (Fig. S7C). We thus questioned whether Topo II inhibition plays a critical role in mediating therapeutic efficacy of osimertinib against EGFRm NSCLC or whether osimertinib exerts Topo II inhibitory activity, leading to DNA damage and subsequent apoptotic cell death in EGFRm NSCLC cells. Therefore, we first examined the effect of osimertinib on modulating the levels of Topo II in different EGFRm NSCLC cell lines and found that osimertinib effectively decreased the levels of Topo II $\alpha$  in a concentration-dependent manner in four different EGFRm NSCLC cell lines including PC-9, HCC827, H1975 and SH416 (Fig. 3A). However, osimertinib, under the same tested condition, did not reduce the levels of Topo II $\beta$ , another isoform of human Topo II (Fig. S8). The reduction of Topo II $\alpha$  occurred early at 8 h and was sustained to 24 h in both PC-9 and HCC827 cell lines (Fig. 3B). Furthermore, other EGFR-TKIs including erlotinib (1<sup>st</sup> generation), afatinib (2<sup>nd</sup> generation), EGF816 (3<sup>rd</sup> generation), CO1686 (3<sup>rd</sup> generation) and HS-10296 (3<sup>rd</sup> generation) also decreased Topo II $\alpha$  levels in these cell lines (Fig. 3C). As expected, osimertinib even at 500 nM did not decrease Topo II $\alpha$  levels in NSCLC cell lines with WT *EGFR* gene (Fig. 3D). In both PC-9 and HCC827 xenografted tumor tissues treated with osimertinib for 9 days, Topo II $\alpha$  levels were clearly decreased in comparison with their corresponding control tissues exposed to vehicle (Fig. 3E). These results together demonstrate that osimertinib as well other EGFR-TKIs decrease Topo II $\alpha$  levels in EGFRm NSCLC cells and tissues.

We next determined whether osimertinib-induced Topo II $\alpha$  is accompanied with enhanced DNA double strand breaks (DSBs) or damage by detecting  $\gamma$ -H2AX foci formation, a classical assay for detection of DNA DSBs (11, 12). In both PC-9 and HCC827 cells, we detected cells

positive for  $\gamma$ -H2AX foci staining, which were hardly detected in DMSO-treated control cells (Fig. 3F). Hence, it is clear that osimertinib induces DNA damage in EGFRm NSCLC cells.

We further determined whether Topo II $\alpha$  reduction is a critical event contributing to induction of DNA damage and apoptosis by osimertinib in EGFRm NSCLC. To this end, we enforced overexpression of an ectopic *TOP2A* gene in both PC-9 and HCC827 cells and then checked their responses to osimertinib in terms of DNA damage, apoptosis induction and cell survival. The results show that osimertinib effectively induced PARP cleavage, increased annexin V-positive cells and decreased cell survival in vector control cells, but had reduced effects in *TOP2A*-expressing cells (Figs. 3G-I). Consistently, osimertinib increased  $\gamma$ -H2AX foci staining in vector control cells, but only weakly in *TOP2A*-expressing cells (Fig. 3J). These data clearly demonstrate that enforced overexpression of the ectopic *TOP2A* gene in EGFRm NSCLC cells attenuates the ability of osimertinib to induce DNA damage and apoptosis and to decrease cell survival, suggesting an essential role of Topo II inhibition in mediating therapeutic efficacy of osimertinib against EGFRm NSCLC cells.

**Osimertinib decreases Topo II $\alpha$  levels via promoting GSK3-dependent and FBXW7-mediated proteasomal degradation and suppressing *SMURF2* expression in EGFRm NSCLC cell lines.** To understand the molecular mechanism by which osimertinib decreases Topo II $\alpha$  levels in EGFRm NSCLC cells, we studied mRNA levels and found that osimertinib did not alter *TOP2A* mRNA levels (Fig. 4A), suggesting a possible post-transcriptional mechanism. Considering that Topo II $\alpha$  levels are modulated by a post-translational mechanism (13), we then determined the impact of proteasome inhibition on Topo II $\alpha$  reduction induced by osimertinib and found that the presence of the proteasome inhibitor, MG132, abolished the ability of osimertinib to decrease Topo II $\alpha$  levels in both PC-9 and HCC827 cell lines (Fig. 4B). Moreover, Topo II $\alpha$

was degraded much faster in both PC-9 and HCC827 cells exposed to osimertinib than in DMSO-treated cells as demonstrated in the cycloheximide (CHX) chase assay (Fig. 4C). Together, we conclude that osimertinib facilitates proteasomal degradation of Topo II $\alpha$ , leading to Topo II $\alpha$  reduction in EGFRm NSCLC cells.

Smurf2 is a protein E3 ubiquitin ligase that is involved in positive regulation of Topo II $\alpha$  degradation via modifying Topo II $\alpha$  ubiquitination status by reducing degradation promoting K48 polyubiquitination and increasing monoubiquitination (14). We noted that *SMURF2* gene expression was significantly decreased in both PC-9 and HCC827 cells as revealed in our RNA-seq analysis (Fig. 4D). Smurf2 protein reduction in EGFRm NSCLC cells exposed to osimertinib was also confirmed with Western blotting (Fig. 4E). The presence of MG132 did not rescue Smurf2 reduction caused by osimertinib (Fig. S9), supporting its modulation by osimertinib at a transcriptional level. To determine whether there is a connection between Smurf2 suppression and Topo II $\alpha$  degradation, we knocked down *SMURF2* gene expression with either small interfering RNA (siRNA) or short-hairpin RNA (shRNA) in EGFRm NSCLC cells and then examined Topo II $\alpha$  alterations in these cell lines. Topo II $\alpha$  levels were decreased in cells transfected with *SMURF2* siRNA or infected with *SMURF2* shRNA lentiviruses (Figs. 4F and G). Moreover, knockdown of *SMURF2* gene in both PC-9 and HCC827 cell lines facilitated the degradation of Topo II $\alpha$  in the CHX chase assay (Fig. 4H). In contrast, enforced overexpression of an ectopic *SMURF2* gene in these cell lines elevated basal levels of Topo II $\alpha$  and attenuated the ability of osimertinib to decrease Topo II $\alpha$  levels (Fig. 4I). These data together strongly suggest that Smurf2 downregulation is tightly linked to Topo II $\alpha$  degradation in EGFRm NSCLC cells exposed to osimertinib.

To identify the actual E3 ubiquitin ligase that mediates Topo II $\alpha$  polyubiquitination and subsequent proteasomal degradation, we focused on FBXW7 since Topo II $\alpha$  was demonstrated to undergo GSK3-dependent and FBXW7-mediated proteasomal degradation (15), whereas osimertinib induces GSK3-dependent and FBXW7-mediated degradation of SREBP1 in EGFRm NSCLC cells as we recently demonstrated (16). In the presence of the GSK3 inhibitor, either CHIR99021 or SB216763, osimertinib had diminished effects on reducing Topo II $\alpha$  levels in both PC-9 and HCC827 cells (Fig. 4J). Similarly, knockdown of GSK3 in these cell lines rescued Topo II $\alpha$  reduction induced by osimertinib (Fig. 4K). Consistently, knockdown of FBXW7 with either siRNA or shRNA in these cell lines prevented osimertinib-induced Topo II $\alpha$  reduction as well (Fig. 4M and N). Collectively, these results clearly demonstrate that osimertinib induces GSK3-dependent and FBXW7-mediated proteasomal degradation of Topo II $\alpha$ .

**Topo II $\alpha$  levels are elevated in osimertinib-resistant cell lines and in EGFRm NSCLC tissues relapsed from EGFR-TKI treatment.** To further elucidate the critical role of Topo II $\alpha$  in mediating the response of NSCLC cells to osimertinib or EGFR-TKIs, we compared basal levels of Topo II $\alpha$  between osimertinib-resistant cell lines and their matched parental cell lines and found that Topo II $\alpha$  levels were in general higher in the tested osimertinib-resistant cell lines than in their corresponding parental cell lines (Figs. 5A and B). Osimertinib treatment had little or no effect on decreasing Topo II $\alpha$  levels in these resistant cell lines, in contrast to its effects on Topo II $\alpha$  in the parental cell lines (Fig. 5A). We also detected Topo II $\alpha$  in paired tissues from patients with EGFRm NSCLC receiving EGFR-TKI treatment including osimertinib and found that Topo II $\alpha$  levels were in general significantly elevated in tissues relapsed from the treatment compared with their baseline levels (Fig. 5C). Specifically, we detected Topo II $\alpha$  elevation in 64% (14/22) of relapsed EGFRm NSCLC tissues (Fig. 5D) with strong positive staining in some cases (e.g.,

patients #6, #7 and #16; Fig. 5E). Hence, Topo II $\alpha$  levels are elevated not only in osimertinib-resistant EGFRm NSCLC cell lines, but also in EGFRm NSCLC tissues relapsed from EGFR-TKI treatment.

To have an insight into the mechanism of elevated Topo II $\alpha$  in osimertinib-resistant cell lines, we detected the levels of Smurf and FBXW7 in EGFRm NSCLC cell lines and their derived osimertinib-resistant cell lines. In a similar way to Topo II $\alpha$ , Smurf levels were elevated in the osimertinib-resistant cell lines. In contrast, FBXW7 levels were lower in these resistant cell lines than their matched parental cell lines (Fig. 5F). We also compared *TOP2A* mRNA levels between osimertinib-resistant cell lines and their matched parental cell lines and found that *TOP2A* mRNA expression was not significantly elevated in the osimertinib-resistant cell lines (Fig. 5G). Finally, we conducted the CHX assay to compare the stabilities of Topo II $\alpha$  between PC-9 and PC9/AR cell lines and found that Topo II $\alpha$  was degraded much faster in PC-9 cells than in PC-9/AR cells (Fig. 5H), suggesting increased stability of Topo II $\alpha$  in PC-9/AR cells. These results together strongly suggest that Topo II $\alpha$  elevation in the osimertinib-resistant cell lines is likely due to the alterations of Smurf and FBXW7 that lead to stabilization of Topo II $\alpha$ .

**Genetic knockdown of *TOP2A* in osimertinib-resistant cell lines restores cell responses to osimertinib in inducing DNA damage and apoptosis.** If elevated Topo II $\alpha$  plays a critical role in conferring resistance to osimertinib, we speculated that enforced suppression of *TOP2A* expression by gene knockdown in osimertinib-resistant cell lines should restore their sensitivity to osimertinib. As presented in Fig. 6, knockdown of *TOP2A* with either siRNA or shRNA in both PC-9/AR and HCC827/AR cell lines sensitized the cells to undergo apoptosis as demonstrated by increased PARP cleavage (Figs. 6A and B) and annexin V-positive cells (Figs. 6C and D). Consistently, osimertinib was much more active in decreasing the survival of both PC-9/AR and

HCC827/AR cells expressing shTOP2A while did so only minimally in their corresponding control cells (Fig. 6E), further demonstrating the effect of Topo II $\alpha$  suppression on sensitizing osimertinib-resistant cells to osimertinib. Moreover, osimertinib failed to induce r-H2AX foci-positive cells in the control PC-9/AR and HCC827/AR cell lines, but clearly increased the number of cells with positive nuclear r-H2AX foci staining in cells transfected with *TOP2A* siRNA (Fig. 6F). Hence, enforced inhibition of Topo II $\alpha$  with gene knockdown in osimertinib resistant cells restores their response to osimertinib in inducing DNA damage, increasing apoptosis and decreasing cell survival.

**Osimertinib in combination with a Topo II inhibitor enhances DNA damage in osimertinib-resistant cells.** As demonstrated above, induction of DNA damage is a critical event for osimertinib to exert its therapeutic activity, which is lost in osimertinib-resistant cell lines and can be restored by genetic knockdown of *TOP2A* expression. Hence, we further determined whether the combination of osimertinib with a Topo II inhibitor leads to enhanced DNA damage in osimertinib-resistant cells. By performing  $\gamma$ -H2AX foci staining, we found that the combination of osimertinib with either DXR or VP-16 effectively enhanced the number of  $\gamma$ -H2AX foci-positive cells, whereas either of the tested agents alone caused little or no increase in  $\gamma$ -H2AX foci-positive cells (Fig. 6G). This finding indicates that the combination of osimertinib with a Topo II inhibitor indeed enhances DNA damage in osimertinib-resistant cells, in agreement with their enhanced induction of apoptosis as demonstrated above.

**The combination of osimertinib and VP-16 exerts augmented therapeutic efficacy against the growth of EGFRm NSCLC patient-derived xenografts (PDXs) and delays emergence of acquired resistance to osimertinib.** Beyond the demonstrated effects of osimertinib combined with a Topo II inhibitor in EGFRm NSCLC cell lines with acquired



resistance to osimertinib, we also examined the effects of these combinations on the growth of a few cell lines with primary resistance to osimertinib isolated from sensitive EGFR<sup>m</sup> PC-9 cells. The rationale is based on our finding that several PC-9-derived cell lines with primary resistance to osimertinib (17) had elevated levels of Topo II $\alpha$  (Fig. 7A). Similar to what we found in EGFR<sup>m</sup> NSCLC cell lines with acquired resistance to osimertinib above, the combination of osimertinib with DXR or VP-16 was more effective than either single agent alone in decreasing the survival of the 3 cell lines with primary osimertinib resistance with CIs of < 1 (Figs. 7B and C), indicating synergistic effects. Beyond the presence of primarily resistant clones in sensitive EGFR<sup>m</sup> NSCLC cell populations as a key mechanism accounting for the emergence of acquired resistance to EGFR-TKIs, drug-tolerant persister cells (DTCs) surviving in the initial period of treatment represent another critical origin accounting for the emergence of acquired resistance (18, 19). We clearly detected DTCs in cells treated with osimertinib alone after a 10-day treatment, but not in cells exposed to the combination of osimertinib and VP-16 (Fig. 7D), indicating that the combination is also effective in eliminating DTCs. Because of these promising findings, we then reasonably asked whether the combination of osimertinib with a Topo II inhibitor such as VP-16 potentiates the growth suppression of EGFR<sup>m</sup> NSCLC tumors and delays emergence of acquired resistance to osimertinib *in vivo*. The three EGFR<sup>m</sup> NSCLC PDXs, TM00193, TM00219 and particularly TM00190, were all responsive to osimertinib treatment albeit with varied sensitivities. Among them, TM00193 was relatively less responsive to osimertinib. It did not respond well to osimertinib in the initial period of treatment, but responded after 20 days although the growth was retarded (Figs. 7E and S10A). TM00219 and particularly TM00190 were relatively sensitive to osimertinib, but did grow back as the treatment times were prolonged (Figs. 7F, 7G, S10B and S10C), indicating emergence of acquired resistance. All three PDXs were sensitive to VP-16 in the initial

period of treatment (e.g., up to 40 days) under the tested conditions and then gradually became less responsive to treatment (Figs. 7E-G and S10), suggesting the development of resistance as well. However, the combination of osimertinib and VP-16 in each model quickly reduced the sizes of tumors even after a few days of treatment. After about 40 days, the tumors were all reduced to minimal sizes; these effects were maintained for over 100 days of treatment (Figs. 7E-G and S10). In the TM00190 model, the tumor suppressive effect of the combination was maintained up to over 170 days while tumors treated with osimertinib alone had started to resume growth (Figs. 7G and S10C). We did not observe regrowth of tumors treated with the combination of osimertinib and VP-16 even after one month of withdrawing the treatment, indicating no relapse. When relapsed tumors treated with osimertinib alone were switched to the combination of osimertinib and VP-16 on day 170, tumor shrinkage was observed (Fig. 7G and S10C), further confirming the efficacy of the combination in overcoming acquired resistance to osimertinib in this PDX model. These results convincingly demonstrate that the inclusion of VP-16 in EGFR-targeted therapy (e.g., with osimertinib) may lead to augmented therapeutic efficacy and delay or even prevent the emergence of acquired resistance. In this study with different EGFRm NSCLC PDXs, mice treated with the combination of osimertinib and VP-16 had comparable body weights to those treated with osimertinib alone even after over 200 days (Fig. S11), indicating the favorable tolerability of the combination while augmenting therapeutic efficacy against the growth of EGFRm NSCLC tumors.

## **Discussion**

Platinum-based chemotherapy is standard of care following development of resistance to osimertinib in the clinic. An open-label randomized phase 2 study that evaluated osimertinib combined with carboplatin-pemetrexed in comparison with osimertinib monotherapy in EGFRm

NSCLC patients who experienced disease progression associated with the emergence of EGFR T790M resistance mutation during first-line EGFR-TKI therapy failed to demonstrate prolongation of progression-free survival (PFS) (20). Other clinical trials with osimertinib plus platinum-pemetrexed in newly diagnosed EGFRm advanced/metastatic NSCLC showed a manageable safety with tolerability profile (21) and significantly prolonged PSF compared with osimertinib alone (22). Nonetheless, the rationale or molecular mechanism for the combination is unclear.

In our study, the combination of osimertinib with any of the agents, CDDP, carboplatin, PTX, gemcitabine, 5-FU, cyclophosphamide, capecitabine and vincristine, did not show enhanced effects on decreasing the survival of osimertinib-resistant cell lines. Consistently, the combinations of osimertinib with CDDP and PTX, respectively, did not show enhanced effects on the suppression of osimertinib-resistant tumors *in vivo* either. Interestingly, DXR and VP-16, both of which share the common action of mechanism, Topo II inhibition, synergized with osimertinib to decrease the survival of osimertinib-resistant cell lines and to suppress the growth of osimertinib-resistant xenografted tumors including PDXs *in vivo*, thus generating interest in this combination. Efforts to demonstrate the underlying biology or scientific rationale in this study have led us to reveal a role of Topo II $\alpha$  modulation in critically mediating the response of EGFRm NSCLC cells to osimertinib and likely other EGFR-TKIs based on the following findings: 1) Osimertinib as well as other EGFR-TKIs effectively decreased the levels of Topo II $\alpha$  via facilitating its proteasomal degradation; this process involves suppression of *SMURF* expression in the sensitive EGFRm NSCLC cell lines and tumors accompanied with induction of DNA damage; 2) Enforced overexpression of the ectopic *TOP2A* gene attenuated the ability of osimertinib to induce DNA damage and apoptosis, conferring resistance to osimertinib; 3) Topo II $\alpha$  levels were elevated in

osimertinib resistant cell lines, likely due to increased protein stability caused by Smurf2 elevation and FBXW7 reduction, and in the majority of EGFR<sup>m</sup> NSCLC tissue relapsed from EGFR-TKI treatment and were resistant to osimertinib modulation; and 4) Enforced reduction of Topo II $\alpha$  levels via gene knockdown restored the responses of osimertinib-resistant cell lines to undergo DNA damage and apoptosis upon osimertinib treatment. Collectively, the current study has convincingly demonstrated an essential role of Topo II $\alpha$  inhibition in mediating the therapeutic efficacy of osimertinib against EGFR<sup>m</sup> NSCLC cells and the scientific rationale for targeting Topo II to overcome acquired resistance to osimertinib. We realized the general limitation of gene overexpression strategy that often results in supra-physiologic levels of a tested protein. Under the specific scenario that Topo II $\alpha$  levels were highly elevated in osimertinib-resistant EGFR<sup>m</sup> NSCLC cell lines, enforced expression of ectopic *TOP2A* gene in the sensitive EGFR<sup>m</sup> NSCLC cell lines with low levels of Topo II $\alpha$  may mimic the situation in the resistant cell lines. Outcomes from this study should provide complementary support to *TOP2A* knockdown results for demonstrating the critical role of Topo II inhibition in mediating the therapeutic efficacy of osimertinib in EGFR<sup>m</sup> NSCLC cells.

Both DXR and VP-16 have long been used for the treatment of cancers although less frequently in NSCLC. Our findings thus warrant the clinical validation of this therapeutic strategy to overcome osimertinib acquired resistance. It is well known that human cells express both Topo II $\alpha$  and Topo II $\beta$  enzymes (23, 24). Topo II $\beta$  was previously identified as a major cellular target for DXR-induced cardiotoxicity (25). In this study, osimertinib at concentrations up to 500 nM did not reduce the levels of Topo II $\beta$ , indicating its selectivity in targeting Topo II $\alpha$ . In our *in vivo* animal study, the combination of osimertinib with either DXR or VP-16 was well tolerated in nude mice without apparently increasing toxicity (i.e., body weight loss). In agreement, the treatment of

regular immunocompetent mice with the combinations did not show the increased toxicity either, further indicating their safety. One limitation of the study is that the majority of the mechanistic findings were primarily generated from PC-9 and HCC827 cell lines although they are widely used in the community. This is largely due to the limited availability of characterized EGFRm cell lines that are sensitive to EGFR-TKIs.

One important finding is that Topo II $\alpha$  levels were elevated in several EGFRm NSCLC cell lines with acquired resistance to osimertinib, which was confirmed in over 60% of EGFRm NSCLC tissues from patients relapsed following treatment with EGFR-TKIs including osimertinib, constituting a critical foundation for targeting Topo II to overcome acquired resistance to osimertinib and possibly other EGFR-TKIs. It is very likely that this strategy may work well in relapsed NSCLC with elevated Topo II $\alpha$  expression. Therefore, Topo II $\alpha$  elevation may be used as a predictive biomarker for selecting patients with disease relapse from osimertinib treatment to receive this therapeutic strategy, i.e., the combination of osimertinib with a Topo II inhibitor such as VP-16.

Instead of passively waiting until the development of acquired resistance, another sound and active strategy for managing the acquired resistance is to delay or prevent the inevitable emergence of acquired resistance through an early preventive intervention before disease progression, which can be achieved by using effective and tolerable combination regimens that interfere with the process of developing acquired resistance (19). VP-16 has long been used for the treatment of cancers although less frequently NSCLC. Therefore, its safety profile in patients is well known to oncologists and expected to be manageable. In this study, the combination of osimertinib and VP-16 potentiated the growth suppression of three different EGFRm NSCLC PDXs compared with the efficacy of each single agent. Tumors receiving the combination treatment regressed to

minimal or undetectable sizes without relapse over a long treatment period of more than 100 days. Strikingly, tumors remained suppressed with no sign of regrowth after withdrawal of the combination treatment for over 30 days. Beyond this promising efficacy, we did not observe enhanced toxicity in mice even up to 200 days, indicating that the combination treatment is well tolerated in mice. The promising effect of this combination on delaying or preventing the emergence of acquired resistance is largely due to its effectiveness in eliminating both primarily resistant clones and DTCs present in the EGFR<sup>m</sup> NSCLC cell population, which both constitute a key mechanism accounting for the emergence of acquired resistance to EGFR-TKIs including osimertinib (18, 19). Hence, our findings in this regard warrant the clinical evaluation of the osimertinib and VP-16 combination in patients with EGFR<sup>m</sup> NSCLC as an effective regimen to delay or prevent the emergence of acquired resistance and prolong patient survival. VP-16 has been primarily used in the treatment of SCLC (26, 27). One interesting mechanism accounting for the development of acquired resistance to osimertinib is the transformation of SCLC (4, 28). This provides additional rationale for using VP-16 early in combination with osimertinib to delay or prevent the emergence of acquired resistance to osimertinib.

Smurf2 is a HECT-type E3 ubiquitin ligase and functions as a physiologic regulator of Topo II $\alpha$  levels through physically interacting with Topo II $\alpha$  and modifying its ubiquitination status by reducing degradation-promoting K48 polyubiquitination and increasing monoubiquitination that protects Topo II $\alpha$  from proteasomal degradation (14). Indeed, we have demonstrated that suppression of *SMURF2* expression is tightly involved in the regulation of osimertinib-induced Topo II $\alpha$  degradation because enforced overexpression of the ectopic *SMURF2* gene in EGFR<sup>m</sup> NSCLC cells elevated basal levels of Topo II $\alpha$  and attenuated the ability of osimertinib to decrease Topo II $\alpha$  levels, while knockdown of *SMURF2* expression resulted in facilitation of Topo II $\alpha$

degradation and substantial reduction of Topo II $\alpha$  levels in these cell lines. However, Smurf2 is not the E3 ubiquitin ligase responsible for the polyubiquitination and degradation of Topo II $\alpha$  induced by osimertinib. In this study, we further suggest that osimertinib induces proteasomal degradation of Topo II $\alpha$ , likely via a GSK3-dependent and FBXW7-mediated mechanism, in EGFRm NSCLC cells since inhibition of either GSK3 or FBXW7 rescued Topo II $\alpha$  reduction induced by osimertinib. This is consistent with our previous finding that osimertinib promotes GSK3-dependent and FBXW-mediated degradation of the mature form of SREBP1 in EGFRm NSCLC cells (16). Hence, we suggest that osimertinib decreases Topo II $\alpha$  levels via promoting GSK3-dependent and FBXW7-mediated proteasomal degradation in coordination with suppression of *SMURF2* expression in EGFRm NSCLC cell lines. Osimertinib is known to inhibit Akt phosphorylation or activity (16, 17). Since GSK3 is a well-known substrate of Akt, it is likely that osimertinib inhibits Akt-dependent GSK3 phosphorylation in EGFRm NSCLC cells, leading to GSK3 activation and subsequent GSK3-dependent and FBXW7-mediated degradation of Topo II $\alpha$ . This speculation may need further investigation in the future.

In summary, our work has revealed an essential role of Topo II $\alpha$  modulation in regulating the responses of EGFRm NSCLC cells to osimertinib; this provides a strong scientific rationale for managing acquired resistance to osimertinib and possibly other third generation EGFR-TKIs via targeting Topo II. Our finding thus warrants clinical validation of co-targeting EGFR and Topo II as an effective strategy to enhance the therapeutic efficacy of EGFR-targeted therapy and manage acquired resistance to osimertinib and other EGFR-TKIs.

## **Materials and Methods**

**Sex as a biological variable.** Lung cancer is not a sex-specific cancer. Human lung cancer tissues were collected from both female and male patients. Both female and male mice were used in the study.

**Reagents.** The chemotherapeutic drugs, VP-16, DXR, PTX, CDDP, carboplatin, gemcitabine, fluorouracil (5-FU), cyclophosphamide, capecitabine and vincristine were purchased from MedChemExpress (MCE; Monmouth Junction, NJ). Topo II $\alpha$  (#12286), Smurf2 (#12024), cPARP (#5625) and Bim (#2933) antibodies were purchased from Cell Signaling Technology, Inc (Beverly, MA). Mcl-1 (sc-12756) and Topo II $\beta$  (sc-55330) antibodies were purchased from Santa Cruz Biotechnology. Anti-phospho-histone H2AX (Ser139;  $\gamma$ -H2AX) antibody was purchased from MilliporeSigma (Cat # 05-636; St. Louis, MO). DAPI (Cat # 62248) and secondary antibody Alexa Fluor 488-Donkey anti-mouse (A32766) were purchased from Thermo Fisher Scientific (Waltham, MA). Other reagents and antibodies were the same as described previously (10, 16).

**Cell lines and cell culture.** All cell lines used in this study were described previously (17, 29, 30). PC-9/AR/Bim-KO and HCC827/AR/Bim-KO were established using the same method as described in our previous study (29). Cell lines that stably overexpress the *TOP2A* gene were established with infection of lentiviruses carrying a human *TOP2A* gene that encodes Topo II $\alpha$  protein followed by kanamycin selection. *TOP2A* lentiviral plasmid (Cat# 444860610195) and matching vector pLenti-GIII-CMV were purchased from Applied Biological Materials (abm) Inc. (Richmond, BC, Canada) and used as instructed by the manufacturer. These cell lines have not been genetically authenticated. All cell lines were cultured in RPMI1640 medium supplemented with 5% FBS at 37°C in 5% CO<sub>2</sub> humidified air.

**Colony formation assay.** The tested cell lines were seeded in 12-well plates at a density of 150 or 200 cells/well for 24 h and then exposed to the tested drugs. The medium was replaced with



fresh medium containing the same drugs every 3 days. After incubation for 10 days, the medium was removed. The plates were then fixed and stained with 2% crystal violet in ethanol for colony counting (> 50 cells/well) and photographing.

**Cell survival assay.** Cells were seeded in 96-well plates at appropriate densities and on the second day were exposed to drug treatments either alone or in combination for 3 days. Cell numbers were measured by sulforhodamine B (SRB) assay as previously described (31). CI for drug interaction was calculated with the CompuSyn software (ComboSyn, Inc; Paramus, NJ).

**Apoptosis assays.** Apoptosis was evaluated with the annexin V/7-AAD apoptosis detection kit (BD Biosciences; San Jose, CA) according to the manufacturer's protocol. Apoptosis was also demonstrated by protein cleavages detected with Western blotting.

**Western blot analysis.** The procedures used for the preparation of the whole-cell protein lysates and immunoblotting were described previously (10). Protein band intensities were quantified by NIH ImageJ software.

**$\gamma$ -H2AX foci assay.** Cells were seeded in chamber slides and then treated with the tested drugs. After different times, the cells were fixed with 4% paraformaldehyde for 10 min and then blocked with 5% BSA and 0.2% Triton-X100 in PBS buffer for 1 h at room temperature. The cells were incubated with  $\gamma$ -H2AX antibody (1:100 dilution) at 4°C overnight and then incubated with the secondary antibody Alexa Fluor 488-Donkey anti-mouse (1:200 dilution) for 2 h at room temperature followed by DAPI (1:1000) counterstain. Images were collected using a confocal microscope (Leica TCS SP8; Leica Camera, Wetzlar, Germany).

**Protein stability assay.** Cells were treated with DMSO or osimertinib for a given time followed by addition of fresh medium with 10  $\mu$ g/ml CHX and then harvested at different times for preparation of whole-cell protein lysates and subsequent Western blot analysis.

**Detection of DTCs.** Cells seeded in 12-well plates at a density of close to 90% were exposed to the tested drugs. The medium was replaced with fresh medium containing the same drugs every 2 days. After incubation for 5 or 10 days, the medium was removed for fixing and staining DTCs with 2% crystal violet in ethanol.

**Quantitative reverse transcription PCR (RT-qPCR).** Cellular total RNA was extracted using an RNA extraction kit (Qiagen; Germantown, MD) according to the manufacturer's instructions. The concentrations were measured with NanoDrop (Thermo Fisher Scientific) and reverse transcription was carried out using the RevertAid First Strand cDNA Synthesis Kit (Qiagen). qPCRs were performed at 95°C for 15 s followed by 40 cycles of 95°C for 5 s and 60°C for 30 s using the QuantStudio 3 and 5 systems (Thermo Fisher Scientific). GAPDH was used as an endogenous control. The primers are as follows: TOP2A, 5'-GTGGCAAGGATTCTGCTAGTCC-3' (forward) and 5'-ACCATTCAGGCTCAACACGCTG-3' (reverse); GAPDH, 5'-GTCTCCTCTGACTTCAACAGCG-3' (forward) and 5'-ACCACCCTGTTGCTGTAGCCAA-3'.

**Gene knockdown using siRNA) and shRNA.** TOP2A siRNA (sc-36695), TOP2A shRNA plasmid (sc-36695-SH), SMURF2 siRNA (sc-41675) and SMURF2 shRNA plasmid (sc-41675-SH) were purchased from Santa Cruz Biotechnology. Scrambled control, GSK3 $\alpha/\beta$  and FBXW7 siRNAs, FBXW7 shRNA and the procedures used for transfection were described previously (16).

**TCGA data analysis.** The comparison of TOP2A expression between lung adenocarcinoma (LUAD; n = 483) and normal (n = 347) samples were conducted using GEPIA2 (32), where LUAD samples came from TCGA and normal samples came from both TCGA and GTEx data. Kaplan-Meier analysis was performed using EGFR TKI-treated patient data retrieved from

TCGA LUAD datasets (<http://cancergenome.nih.gov/>). Patients were stratified according to high versus low expression (cutoff: median) of *TOP2A* within their tumors.

**Human NSCLC tissues.** Paired tissue samples from patients with EGFRm NSCLC before treatment (i.e., baseline) and after disease relapse from treatment with first generation EGFR-TKIs including gefitinib, erlotinib or icotinib or osimertinib were collected at the Second Xiangya Hospital (Changsha, Hunan, China) and Henan Cancer Hospital (Zhengzhou, Henan, China) under Ethics Review Committee (IRB)-approved protocols (Xiangya IRB2019-009, Henan IRB2019-067 and Emory IRB00104138). All tissues were sent to and stained at the Second Xiangya Hospital.

**Immunohistochemistry (IHC).** Topo II $\alpha$  in human NSCLC tissues was stained with IHC using the EnVision™ + Dual Link System-HRP Kit (Dako; Carpinteria, CA). After tissue sections were deparaffinized and rehydrated, high-temperature antigen retrieval was achieved by heating the samples in EDTA (1:50, pH 9.0) with a pressure cooker for 7 min followed by an incubation with 3% H<sub>2</sub>O<sub>2</sub> to block endogenous peroxidase activity for 30 min. The tissue sections were then incubated with the ready-to-use Topo II $\alpha$  antibody (Cat# MAB-7099; Maixin Biotech, Fuzhou, China) overnight at 4°C followed by an incubation with the secondary antibody (MaxVision™ HRP-Polymer anti-Mouse/Rabbit IHC Kit, Cat# KIT-5030; Maixin Biotech, Fuzhou, China) at room temperature for 30 min. Color reaction was developed by using 3, 3'-diaminobenzidine tetrachloride (DAB) chromogen solution. All slides were counterstained with hematoxylin. Positive control slides were included in every experiment in addition to the internal positive controls. The percentage of positive staining in tumor cells was scored. The staining of slides with xenografted tumor tissues was the same as described previously (16). The dilutions of antibodies used were 1: 100 (Topo II $\alpha$ ), 1:50 (cPARP), 1: 200 (Bim) and 1:100 (Mcl-1), respectively.

**Animal xenograft and treatments.** Animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Emory University. In the conventional cell-derived xenograft studies, cells suspended in sterile PBS at  $3 \times 10^6$  per mouse were injected into the flank of 4-week old nu/nu nude mice purchased from The Jackson Laboratory (Bar Harbor, Maine). On day 7, when the average tumor was around  $80 \text{ mm}^3$ , the mice were divided into groups with equal average tumor volumes and body weights. The following treatments were administered daily: vehicle, osimertinib (5 mg/kg, og), VP-16 (1 mg/kg, ip), DXR (2 mg/kg, ip) and the combination of osimertinib and VP-16 or DXR. Tumor volume was measured using calipers every 2 or 3 days and calculated by  $V = \pi(\text{length} \times \text{width}^2)/6$ . Body weight was also measured every 2 or 3 days. At the end of the experiment, mice were sacrificed using  $\text{CO}_2$ . The tumors were then removed, weighed and stored in formalin for further analysis. The same treatments were also applied to the immunocompetent C57BL/6J mice, which were purchased from The Jackson Laboratory. Evaluation of major mouse organ tissues with H&E staining was conducted in Cancer Tissue and Pathology Shared Resource of Winship Cancer Institute at Emory University. Biochemical tests of serum protein markers and blood cell counting were performed in the Department of pathology at the College of Veterinary Medicine, University of Georgia (Athens, GA).

In PDX studies, the three PDXs harboring different EGFR mutations, TM00193 (E746\_A750del), TM00199 (L858R) and TM00219 (E746\_A750del; T790M; exon 19 del), were purchased from The Jackson Laboratory. When the average tumor was around  $100 \text{ mm}^3$ , the mice were treated with vehicle, osimertinib (5 mg/kg, og), VP-16 (1 mg/kg, ip) and the combination of osimertinib with VP-16 every day. Tumor volume was measured using calipers every 3 or 4 days. At the end of the experiment, mice were sacrificed using  $\text{CO}_2$ . The tumors were then removed, weighed and stored in formalin for further analysis.

**Statistical analysis.** Statistical differences between two groups were determined by two-sided unpaired or paired Student's t-test. One-way ANOVA test was conducted to value differences among multiple groups. Results are presented as means  $\pm$  SDs or SEs. All statistical analyses were conducted using Graphpad Prism 9.0 software. P values less than 0.05 were considered statistically significant.

**Study approval.** Animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Emory University. Human lung cancer tissue collection was conducted under Ethics Review Committee (IRB)-approved protocols (Xiangya IRB2019-009, Henan IRB2019-067 and Emory IRB00104138).

**Data Availability.** All data were presented in this report (please see “Supporting data values: and “Raw data for Western blotting” and also available upon reasonable request.

### **Author contribution**

**ZC**, conceptualization, methodology, investigation, formal analysis, data curation, visualization, writing-original draft preparation; **KAV**, investigation, resources writing-review and editing; **DW**, investigation. **ZQ**: investigation and formal analysis; **SF**, formal analysis, resources, supervision and writing-review & editing, **QW**, resources and writing-review & editing; **TL**, funding acquisition and writing-reviewing & editing; **SSR**, funding acquisition and writing-reviewing & editing; **SYS**, conceptualization, formal analysis, visualization, supervision, funding acquisition, project administration and writing-original draft preparation.

## **Acknowledgements**

We are grateful to Dr. Anthea Hammond in our department for editing the manuscript. We are also thankful to Dr. Zhenxing Guo who is currently in School of Data Science, The Chinese University of Hong Kong-Shenzhen (Shenzhen, Guangdong, P. R. China) for helping with TCGA data analysis.

SSR and SYS are Georgia Research Alliance Distinguished Cancer Research Scholar.

This work was supported by NIH/NCI R01 CA223220 (to SYS), R01 CA245386 (SYS) and UG1 CA233259 (to SSR/TL) and Emory Winship Cancer Institute lung cancer research pilot funds (to SYS).

## References

1. Siegel RL, Miller KD, Fuchs HE, and Jemal A. Cancer statistics, 2022. *CA: a cancer journal for clinicians*. 2022;72(1):7-33.
2. Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. *N Engl J Med*. 2020;382(1):41-50.
3. Piper-Vallillo AJ, Sequist LV, and Piotrowska Z. Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review. *J Clin Oncol*. 2020;JCO1903123.
4. Blaquier JB, Ortiz-Cuaran S, Ricciuti B, Mezquita L, Cardona AF, and Recondo G. Tackling osimertinib resistance in EGFR mutant non-small cell lung cancer. *Clin Cancer Res*. 2023.
5. Gomatou G, Syrigos N, and Kotteas E. Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options. *Cancers*. 2023;15(3).
6. Olausson KA, and Postel-Vinay S. Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 2016;27(11):2004-16.
7. Lee A, Yuan Y, Eccles L, Chitkara A, Dalen J, and Varol N. Treatment patterns for advanced non-small cell lung cancer in the US: A systematic review of observational studies. *Cancer Treat Res Commun*. 2022;33(100648).
8. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. *Nat Rev Cancer*. 2009;9(5):338-50.




9. Fillmore CM, Xu C, Desai PT, Berry JM, Rowbotham SP, Lin YJ, Zhang H, Marquez VE, Hammerman PS, Wong KK, et al. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. *Nature*. 2015;520(7546):239-42.
10. Shi P, Oh YT, Deng L, Zhang G, Qian G, Zhang S, Ren H, Wu G, Legendre B, Jr., Anderson E, et al. Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation. *Clin Cancer Res*. 2017;23(21):6567-79.
11. Sharma A, Singh K, and Almasan A. Histone H2AX phosphorylation: a marker for DNA damage. *Methods Mol Biol*. 2012;920(613-26).
12. Ivashkevich A, Redon CE, Nakamura AJ, Martin RF, and Martin OA. Use of the gamma-H2AX assay to monitor DNA damage and repair in translational cancer research. *Cancer Lett*. 2012;327(1-2):123-33.
13. Ma Y, North BJ, and Shu J. Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: clinical implications for cancer chemotherapy. *Molecular biology reports*. 2021;48(9):6589-601.
14. Emanuelli A, Borroni AP, Apel-Sarid L, Shah PA, Ayyathan DM, Koganti P, Levy-Cohen G, and Blank M. Smurf2-Mediated Stabilization of DNA Topoisomerase IIalpha Controls Genomic Integrity. *Cancer Res*. 2017;77(16):4217-27.
15. Chen MC, Chen CH, Chuang HC, Kulp SK, Teng CM, and Chen CS. Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIalpha degradation in hepatocellular carcinoma cells. *Hepatology*. 2011;53(1):148-59.

16. Chen Z, Yu D, Owonikoko TK, Ramalingam SS, and Sun SY. Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib. *Oncogene*. 2021.
17. Gu J, Yang W, Shi P, Zhang G, Owonikoko TK, Ramalingam SR, and Sun SY. MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of EGFR-mutant lung cancers *Cancer*. 2020;126(16):3788-99.
18. Cabanos HF, and Hata AN. Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer. *Cancers*. 2021;13(11).
19. Sun SY. Taking early preventive interventions to manage the challenging issue of acquired resistance to third-generation EGFR inhibitors. *Chinese Medical Journal Pulmonary and Critical Care Medicine*. 2023;in press(
20. Tanaka K, Asahina H, Kishimoto J, Miyata Y, Uchida T, Watanabe K, Hamai K, Harada T, Tsubata Y, Sugawara S, et al. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial. *Eur J Cancer*. 2021;149(14-22).
21. Planchard D, Feng PH, Karaseva N, Kim SW, Kim TM, Lee CK, Poltoratskiy A, Yanagitani N, Marshall R, Huang X, et al. Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study. *ESMO Open*. 2021;6(5):100271.
22. Planchard D, Janne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. *N Engl J Med*. 2023;389(21):1935-48.


23. Bjornsti MA, and Kaufmann SH. Topoisomerases and cancer chemotherapy: recent advances and unanswered questions. *Fl000Res*. 2019;8(
24. Pommier Y, Nussenzweig A, Takeda S, and Austin C. Human topoisomerases and their roles in genome stability and organization. *Nat Rev Mol Cell Biol*. 2022;23(6):407-27.
25. Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, and Yeh ET. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. *Nat Med*. 2012;18(11):1639-42.
26. Oronsky B, Abrouk N, Caroën S, Lybeck M, Guo X, Wang X, Yu Z, and Reid T. A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC). *Journal of Cancer*. 2022;13(9):2945-53.
27. Hayashi R, and Inomata M. Small cell lung cancer; recent advances of its biology and therapeutic perspective. *Respir Investig*. 2022;60(2):197-204.
28. Zalaquett Z, Catherine Rita Hachem M, Kassis Y, Hachem S, Eid R, Raphael Kourie H, and Planchard D. Acquired resistance mechanisms to osimertinib: The constant battle. *Cancer Treat Rev*. 2023;116(102557).
29. Chen Z, Vallega KA, Chen H, Zhou J, Ramalingam SS, and Sun SY. The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition. *Pharmacological research*. 2022;175(105998).
30. Zhu L, Chen Z, Zang H, Fan S, Gu J, Zhang G, Sun KD, Wang Q, He Y, Owonikoko TK, et al. Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib. *Cancer Res*. 2021;81(18):4822-34.
31. Sun SY, Yue P, Dawson MI, Shroot B, Michel S, Lamph WW, Heyman RA, Teng M, Chandraratna RA, Shudo K, et al. Differential effects of synthetic nuclear retinoid receptor-

selective retinoids on the growth of human non-small cell lung carcinoma cells. *Cancer Res.* 1997;57(21):4931-9.

32. Tang Z, Kang B, Li C, Chen T, and Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. *Nucleic Acids Res.* 2019;47(W1):W556-W60.




**Figure 1. Topo II inhibitors in combination with osimertinib synergistically decrease cell survival (A-C), inhibit colony formation and growth (D and E) and induce Bim-dependent apoptosis (F-J) in osimertinib-resistant EGFRm NSCLC cell lines.** A-C, The given cell lines were treated with 250 nM osimertinib, 1.25 μM VP-16, 125 nM DXR, 5 nM paclitaxel, 10 μM cisplatin, 25 μM carboplatin, 25 nM gemcitabine, 20 nM 5-Fu, 25 μM cyclophosphamide, 25 μM capecitabine or 10 nM vincristine alone and their respective combinations (A) or with varied concentrations of the tested agents either alone or in combinations (B and C) for 3 days. Cell numbers were then measured by the SRB assay. The data means ± SDs of four replicate determinations. \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$  compared with each agent alone. The fixed sub-optimal concentrations of the tested agents used in A were chosen based on their concentration-dependent survival curves. D and E, The tested cell lines seeded in 12-well plates were treated with 50 nM osimertinib, 10 nM (PC-9/AR) or 50 nM (HCC827/AR) DXR, 150 nM VP-16 or the indicated combinations, which were repeated with fresh medium every 3 days. After 10 days, the cells were fixed, stained with crystal violet dye, imaged (D) and counted (E). Columns are means ± SDs of triplicate determinations. F-J, The tested cell lines were exposed to 200 nM osimertinib, 100 nM (PC-9/AR) or 250 nM (HCC827/AR) DXR, 1 μM VP-16 or the indicated combinations for 48 h (F, G, I and J) or 16 h (H). The proteins of interest were detected with Western blotting (F, H and I) and apoptotic cells were detected with annexin V staining/flow cytometry (E and J). Each column represents mean ± SD of triplicate treatments. Statistical differences were conducted with two-sided unpaired Student's t-test for given two groups (J) or one-way ANOVA test (A, E and G) for multiple groups.




**Figure 2. The combination of osimertinib with DXR or VP-16 effectively inhibits the growth of osimertinib-resistant EGFR<sup>m</sup> NSCLC xenografts *in vivo* (A-C) with modulation of several critical protein biomarkers in tumor tissues (D). PC-9/AR or HCC27/AR cells grown in NU/NU mice as xenografted tumors (n = 6/group) were treated with vehicle, osimertinib alone (5 mg/kg, daily, og), DXR alone (1 mg/kg/day, daily, ip), VP-16 alone (1 mg/kg/day, daily, ip) or the indicated combinations. Tumor sizes were measured at the indicated time points (A). At the end of treatment, tumors in each group were also weighed (B) and photographed (C). The data in each group are means  $\pm$  SEs of 6 tumors from 6 mice. The proteins of interest as indicated were stained with IHC. Statistical differences among multiple groups were conducted with one-way ANOVA test.**






**Figure 3. Osimertinib as well as other EGFR-TKIs decreases the levels of Topo II $\alpha$  (A-E) and induces  $\gamma$ -H2AX foci formation (F) in EGFR<sup>m</sup> NSCLC cells and tissues and overexpression of ectopic TOP2A attenuates the effects of osimertinib on inducing apoptosis (G and H), decreasing cell survival (I) and increasing  $\gamma$ -H2AX foci formation (J). A-D**, The given cell lines as indicated were exposed to varied concentrations of osimertinib for 24 h (A), 200 nM osimertinib for different times (B), 200 nM different EGFR-TKIs for 24 h (C) or 500 nM osimertinib for 24 h (D). Proteins of interest were detected with Western blotting. E, Topo II $\alpha$  in tissues was detected with IHC. F and J, The indicated cell lines were exposed to 250 nM osimertinib for 16 h and then stained with anti- $\gamma$ -H2AX antibody and DAPI. DSB inducer here served as a positive control and was used at 100  $\mu$ M for 1 h treatment. G-I, The indicated cell lines were exposed to DMSO or 200 nM osimertinib for 18 h (G) or 24 h (H) or treated with different concentrations of osimertinib for 3 days (I). The proteins of interest were detected with Western blotting (G) and apoptotic cells were detected with annexin V staining/flow cytometry (H). Each column in H represents mean  $\pm$  SD of triplicate treatments. Cell numbers were measured by the SRB assay and expressed as means  $\pm$  SDs of four replicate determinations (I). Statistical differences between two groups were conducted with two-sided unpaired Student's t-test.




**Figure 4. Osimertinib does not affect *TOP2A* transcription (A) but promotes GSK3-dependent and FBXW7-mediated Topo II $\alpha$  protein degradation (B, C and J-N) associated with suppression of *SMURF2* expression (D-I).** A, The tested cell lines were exposed to 200 nM osimertinib for 16 h. *TOP2A* mRNA was detected with RT-qPCR. NS, not significant with two-sided unpaired Student's t-test. B, The tested cell lines were pre-treated with 10  $\mu$ M MG132 for 30 min, then co-treated with DMSO or 200 nM osimertinib for another 6 h. C, Both PC-9 and HCC827 cells were treated with 200 nM osimertinib for 16 h followed by the addition of 10  $\mu$ g/ml CHX and then harvested at the indicated times. D, RNA-seq detection of *SMURF2* mRNA expression in the given cell lines exposed to 100 nM osimertinib for 14 h. E, The tested cell lines were exposed to varied concentrations of osimertinib as indicated for 24 h. F and G, The tested cell lines were transfected with the given siRNAs or infected with lentiviruses carrying the given shRNA for 48 h. H, The tested cell lines were exposed to 10  $\mu$ g/ml CHX and then harvested at different times as indicated. I, The tested cell lines were treated with 200 nM osimertinib for 24 h. J, Both PC-9 and HCC827 were pre-treated with 10  $\mu$ M CHIR99021 or SB216763 for 30 min and then co-treated with 200 nM osimertinib for an additional 16 h. K and M, The tested cell lines were transfected with scrambled, GSK3 (K) or FBXW7 (M) siRNA for 48 h followed by treatment with 200 nM osimertinib for another 24 h. N, The indicated cell lines expressing pLKO.1 or shFBXW7 were exposed to 200 nM osimertinib for 24 h. The proteins in the aforementioned treatments were detected with Western blotting. Band intensities were quantified with NIH Image J software and plotted as % of 0 time (C and H).






**Figure 5. Topo II $\alpha$  levels are elevated in EGFRm NSCLC cell lines with acquired resistance to osimertinib (A and B) and in EGFRm NSCLC tissues relapsed from EGFR-TKI treatment (C-E), which are resistant to osimertinib modulation (A) accompanied with elevated Smurf2 and decreased FBXW7 (F), unchanged mRNA expression (G), and increased stability of Topo II $\alpha$  (H). A, B and F, Whole-cell protein lysates were prepared from the given osimertinib-resistant cell lines exposed to 1000 nM osimertinib (Osim) for 24 h (A) or from untreated given cell lines with similar densities (B and F). The indicated proteins were detected with Western blotting. C-E, Topo II $\alpha$  in human EGFRm NSCLC tissues before and after relapse from treatment using EGFR-TKIs including osimertinib was stained with IHC. Statistical analysis was conducted with two-sided paired Student's t-test. G, TOP2A mRNA expression in the indicated cell lines were detected with RT-qPCR. NS, not significant with two-sided unpaired Student's t-test. H, The tested cell lines were exposed to 10  $\mu$ g/ml CHX and then harvested at different times as indicated for subsequent Western blotting. Band intensities were quantified with NIH Image J software and plotted as % of 0 time.**



**Figure 6. Genetic knockdown of *TOP2A* expression in osimertinib-resistant cells restores their response to osimertinib in inducing apoptosis (A-D), decreasing cell survival (E) and increasing DNA damage (F), similar to the effect of combined osimertinib and Topo II inhibitor on enhancing induction of DNA damage in these resistant cell lines (G). A-E,** PC-9/AR and HCC827/AR cells transfected with scrambled control or *TOP2A* siRNA for 48 h (A and B), or expressing pLKO.1 or sh*TOP2A* (C-E) were exposed to 200 nM osimertinib for 24 h (A and C), 48 h (B and D) or 72 h (E). Topo II $\alpha$  and PARP cleavage were detected with Western blotting (A and C). Annexin V-positive cells were determined with flow cytometry (B and D). Cell numbers were estimated with the SRB assay (E). The data are means  $\pm$  SDs of triplicate (B and D) or four replicate (E) determinations. Statistical analysis was conducted with two-sided unpaired Student's t-test. CF, cleaved form. F, The indicated cell lines were transfected with scrambled control or *TOP2A* siRNA for 48 h and then exposed to 250 nM osimertinib for an additional 24 h. The cells were then subject to detection of  $\gamma$ -H2AX foci using IF staining with anti- $\gamma$ -H2AX antibody. G, The indicated cell lines were treated with DMSO, 250 nM osimertinib, 100 nM (PC-9/AR) or 250 nM (HCC827/AR) DXR, 1  $\mu$ M VP-16 or their respective combinations as indicated for 24 h and then subject to detection of  $\gamma$ -H2AX foci using IF staining with anti- $\gamma$ -H2AX antibody. DSB (100  $\mu$ M for 1 h) here was used as a positive control.



**Figure 7. Osimertinib combined with a Topo II inhibitor synergistically decreases the survival of EGFRm NSCLC cell lines with primary resistance to osimertinib (B and C) expressing elevated levels of Topo II $\alpha$  (A), eliminates DTCs (D) and regresses different EGFRm PDX tumors *in vivo* with long-term remissions (E-G). A, Detection of basal levels of Topo II $\alpha$  in the indicated cell lines with Western blotting. B and C, The given cell lines were exposed to varied concentrations of osimertinib (Osim), DXR or VP-16 alone as indicated and the combination of osimertinib with DXR or VP-16. After 3 days, cell numbers were determined with the SRB assay. The data are means  $\pm$  SDs of four replicate determinations. D, The indicated cell lines seeded in 12-well plates were treated with 50 nM osimertinib, 150 nM VP-16 or their combination; these treatments were repeated with fresh medium every 2 days. After 5 or 10 days, the cells were fixed, stained with crystal violet dye and pictured. E-G, The indicated PDXs in nude mice (6 tumors/group) were treated with vehicle, 5 mg/kg osimertinib (daily, og), 1 mg/kg VP-16 (daily, ip) or the combination of osimertinib and VP-16. The data are means  $\pm$  SEs of 6 tumors.**